This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

PDI Appoints Gerald R. Melillo, Jr. As SVP Of Business Development

PARSIPPANY, N.J., Oct. 10, 2011 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced the appointment of Gerald R. Melillo, Jr. as senior vice president of Business Development, responsible for providing leadership and strategy to help drive PDI's commercial outsource services and contract sales business. He will report to Nancy Lurker, PDI's chief executive officer.

Melillo was most recently general manager of the Southeast Operating Unit for Novartis Pharmaceuticals Corporation, where he was accountable for the operating unit's commercial activities. From 2004 to 2008 at Novartis, he was vice president of the ABGIU Business Franchise, responsible for leading marketing and strategic planning for key in-line brands, multiple brand launches, and key partnerships and joint ventures.

"Gerry brings to PDI a wealth of experience in pharmaceutical industry sales and marketing, proven success in evaluating and closing business transactions, and keen insights into the goals and expectations of our pharmaceutical customers," said Lurker. "He is ideally equipped to lead our business development activities, and I'm confident that Gerry will play an integral role in PDI's future growth. We're delighted to have him aboard."

Melillo said, "PDI is a premier commercial outsource services provider, and I'm excited about joining at a time when pharmaceutical companies are looking to improve their promotional return on investment, reduce expenses and increase efficiency by integrating internal teams with outsourced sales teams. I look forward to working with Nancy and the rest of PDI to grow our market share in contract sales."

Prior to Novartis Pharmaceuticals, Melillo spent 15 years at Pharmacia, Inc. and a predecessor company, Upjohn, which merged with Pharmacia in 1997.

Melillo received a BS degree in Chemistry from Eckerd College, St. Petersburg, Fla.

About PDI, Inc.

PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise.  For more information, please visit the company's website at http://www.pdi-inc.com.

SOURCE PDI, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs